Endometrial carcinoma tumorigenesis and pharmacotherapy research

Minerva Endocrinologica

Volumn 37, Issue 2, 2012, Pages 117-132

  Shu, J ^a   Fang, S ^b   Teichman, P G ^c   Xing, L ^a   Huang, H ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cell transformation, neoplastic; Drug therapy; Endometrial neoplasms

Indexed keywords

ANTHRACYCLINE; BETA CATENIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IXABEPILONE; K RAS PROTEIN; LAPATINIB; LEVONORGESTREL; MEGESTROL ACETATE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PANITUMUMAB; PROGESTERONE; PROTEIN P53; RAPAMYCIN; RIDAFOROLIMUS; SEX HORMONE; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UVOMORULIN;

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; GENETICS; HORMONE ACTION; HUMAN; LIFESTYLE; METABOLIC DISORDER; MISMATCH REPAIR; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PRECANCER; PROGRESSION FREE SURVIVAL; RESEARCH; REVIEW; RISK FACTOR;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, ENDOMETRIOID; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; METFORMIN; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; OBESITY; PROGESTERONE; RISK FACTORS;

EID: 84867309796     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Society; 2012.
2. Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977;59:1055-60. (Pubitemid 8224268)
3. Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes & Control 1999;10:43-9. (Pubitemid 29134751)
4. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2. (Pubitemid 36638434)
5. Voigt LF, Weiss NS. Epidemiology of endometrial cancer. Cancer treatment and research 1989;49:1-21.
6. Karanjgaokar VC, Murphy DJ, Samra JS, Mann CH. Malignant transformation of residual endometriosis after hysterectomy: a case series. Fertil Steril 2009;92:2037 e19-21.
7. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young-women. British Journal of Cancer 1983;47:749-56.
8. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and en dometrial cancer risk - a meta analysis. Obstetrics and Gynecology 1995;85:304-13.
9. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause-the Journal of the North American Menopause Society 2001;8:245-51. (Pubitemid 32645957)
10. Vanleeuwen FE, Benraadt J, Coebergh JWW, Kiemeney L, Gimbrere CHF, Otter R et al. Risk of endometrial cancer after tamoxifen treatment of breast - cancer. Lancet 1994;343:448-52. (Pubitemid 24059587)
11. Romano A, Adriaens M, Kuenen S, Delvoux B, Dunselman G, Evelo C et al. Identification of novel ER-alpha target genes in breast cancer cells: Gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17 beta-estradiol and tamoxifen. Molecular and Cellular Endocrinology 2010;314:90-100.
12. Hardell L, van Bavel B, Lindstrom G, Bjornfoth H, Orgum P, Carlberg M et al. Adipose tissue concentrations of p,p′-DDE and the risk for endometrial cancer. Gynecol Oncol 2004;95:706-11. (Pubitemid 39592541)
13. Xu WH, Xiang YB, Zheng W, Zhang XL, Ruan ZX, Cheng JR et al. Weight history and risk of endometrial cancer among Chinese women. International Journal of Epidemiology 2006;35:159-66. (Pubitemid 43205463)
14. Hosono S, Matsuo K, Hirose K, Ito H, Suzuki T, Kawase T et al. Weight gain during adulthood and body weight at age 20 are associated with the risk of endometrial cancer in Japanese women. J Epidemiol 2011;21:466-73.
15. Hachisuga T, Kaetsu A, Sugimori H, Kamura T, Tsuneyoshi M, Kawarabayashi T. Risk factors for endometrial cancer in Japanese women. International Journal of Gynecological Cancer 1998;8:292-97. (Pubitemid 28432410)
16. Zhang Y, Liu Z, Yu X, Zhang X, Lue S, Chen X et al. The association between metabolic abnormality and endometrial cancer: A large case-control study in China. Gynecologic Oncology 2010;117:41-6.
17. Kaiandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology 1996;53:354-9. (Pubitemid 26283775)
18. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. American Journal of Epidemiology 1997,146:294-306. (Pubitemid 27355565)
19. Jeong N-H, Song E-S, Lee J-M, Lee K-B, Kim M-K, Yun Y-M et al. Preoperative levels of plasma micronutrients are related to endometrial cancer risk. Acta Obstetricia et Gynecologica Scandinavica 2009;88:434-39.
20. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: A population-based prospective cohort study. Cancer Epidemiology Biomarkers & Prevention 2007;16:276-80. (Pubitemid 46383346)
21. Friberg E, Mantzoros CS, Wolk A. Physical activity and risk of endometrial cancer: A population-based prospective cohort study. Cancer Epidemiology Biomarkers & Prevention 2006;15:2136-40. (Pubitemid 44877037)
22. Hjartaker A, Meo MS, Weiderpass E. Alcohol and gynecological cancers: an overview. European Journal of Cancer Prevention 2010;19:1-10.
23. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. British Journal of Cancer 2008;98:1582-85. (Pubitemid 351652323)
24. Hemminki K, Vaittinen P, Dong CH. Endometrial cancer in the family-cancer database. Cancer Epidemiology Biomarkers &. Prevention 1999;8:1005-10. (Pubitemid 29536094)
25. Seger HMM, Soisson AP, Dodson MK, Rowe KG, Cannon-Albright LA. Familial clustering of endometrial cancer in a well-defined population. Gynecologic Oncology 2011;122:75-78.
26. Watson P, Vasen HFA, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal - cancer. American Journal of Medicine 1994;96:516-20. (Pubitemid 24184436)
27. Pistorius S, Kruger S, Hohl R, Plaschke J, Distler W, Saeger H-D et al. Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. Gynecologic Oncology 2006;102:189-94. (Pubitemid 44041645)
28. Buttin BM, Powell MA, Goodfellow PJ, Lewin SN, Gibb RK, Mutch DG. Increased risk for abnormalities on perioperative colon screening in patients with microsatellite instability-positive endometrial carcinoma. International Journal of Gynecological Cancer 2006;16:1980-86. (Pubitemid 44924360)
29. Dumitrescu RG, Cotaria I. Understanding breast cancer risk - where do we stand in 2005? J. Cell. Mol. Med. 2005;9:208-21.
30. Sogaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 2006;85:93-105. (Pubitemid 43879130)
31. Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80:395-8. (Pubitemid 32207542)
32. Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. (Pubitemid 46054134)
33. Duffy DL, Antill YC, Stewart CJ, Young JR, Spurdle AB, kConFab. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families. Twin Research and Human Genetics 2011;14:111-18.
34. Uppal S, Mistry D, Coatesworth AP. Cowden disease: a review. Int J Clin Pract 2007;61:645-52. (Pubitemid 46449842)
35. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008;112:1964-73. (Pubitemid 351574072)
36. Junqueira MG, da Silva IDCG, Nogueira-de-Souza NC, Carvalho CV, Leite DB, Gomes MTV et al. Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development. International Journal of Gynecological Cancer 2007;17:229-32. (Pubitemid 46213995)
37. Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP et al. The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in Non-Hispanic White Women. PLoS One 2011;6.
38. Pothuri B, Ramondetta L, Eifel P, Deavers MT, Wilton A, Alektiar K et al. Radiation-associated endometrial cancers are prognostically unfavorable tumors: A clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecologic Oncology 2006;103.948-51.
39. Parazzini F, Pelucchi C, Talamini R, Montella M, La Vecchia C. Use of fertility drugs and risk of endometrial cancer in an Italian case-control study. European Journal of Cancer Prevention 2010;19:428-30.
40. Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002;105:l66-9.
41. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is asso-ciated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998;17:2413-7. (Pubitemid 28515395)
42. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77. (Pubitemid 32601237)
43. An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 2002;41(5):437-45. (Pubitemid 35335004)
44. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol 2001;158(6):1895-8. (Pubitemid 32545170)
45. Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciris M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract 2007;203(3):153-62.
46. Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 2006;37:1465-72. (Pubitemid 44584324)
47. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBOJ 1997;16:3797-804.
48. Gumbiner BM. Carcinogenesis: a balance between beta-catenin and APC. Curr Biol 1997;7:R443-6.
49. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O, Rice JM. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 1990;50:6139-45. (Pubitemid 20323664)
50. Enomoto T, Fujita M, Inoue M, Rice JM, Nakajima R, Tanizawa O et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993;53:1883-8. (Pubitemid 23127119)
51. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A et al. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Gynecol Oncol 1996;63:238-46. (Pubitemid 26398606)
52. Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2008;27:9-19.
53. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010;70:367-77.
54. Pavelic J, Radakovic B, Pavelic K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol 2007;105:727-35. (Pubitemid 46734203)
55. McGrath M, Lee IM, Buring J, De Vivo I. Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecol Oncol 2011;120:174-8.
56. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Over expression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 2006;12:6373-8. (Pubitemid 44799707)
57. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
58. Semczuk A, Schneider-Stock R, Szewczuk W. Prevalence of allelic loss at TP53 in endometrial carcinomas. Oncology 2010;78:220-8.
59. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Archiv 2004;444:213-23. (Pubitemid 38446432)
60. Kalogiannidis I, Bobos M, Papanikolaou A, Makedos A, Amplianitis I, Vergote I et al. Immunohistochemical bcl-2 expression, p53 over expression, PR and ER status in endometrial carcinoma and survival outcomes. Eur J Gynaecol Oncol 2008;29:19-25. (Pubitemid 351344756)
61. Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA et al. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008;32:307-16. (Pubitemid 351188296)
62. Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002;100:1290-5. (Pubitemid 35449197)
63. Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 2004;10:5546-53. (Pubitemid 39100494)
64. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends in Endocrinology and Metabolism 2011;22:145-52.
65. Zou LB, Zhang RJ, Tan YJ, Ding GL, Shi S, Zhang D et al. Identification of estrogen response element in the aquaporin-2 gene that mediates estrogen-induced cell migration and invasion in human endometrial carcinoma. J Clin Endocrinol Metab 2011;96:E1399-408.
66. Zhou XC, Dowdy SC, Podratz KC, Jiang SW. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 2007;107:143-53. (Pubitemid 47464554)
67. Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D et al. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol 2006;999-18.
68. Burcham PC. Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res 1999;443:11-36. (Pubitemid 29327264)
69. Levina W, Nolen B, Su Y, Godwin AK, Fishman D, Liu J et al. Biological Significance of Prolactin in Gynecologic Cancers. Cancer Research 2009;69:5226-33.
70. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15(l):10-7. (Pubitemid 13194678)
71. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005;99:135-41. (Pubitemid 41354594)
72. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM et al. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 2008;53:525-32.
73. Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomarkers 2011;9:287-305.
74. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998;29:551-8. (Pubitemid 28272707)
75. Zheng W, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-e14.
76. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91. (Pubitemid 46630943)
77. Baak JP, Mutter GL. EIN and WHO94. J Clin Pathol 2005;58:1-6. (Pubitemid 40070487)
78. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4. (Pubitemid 32685749)
79. Landrum LM, Moore KN, Myers TK, Lanneau GS, Jr., McMeekin DS, Walker JL et al. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol 2009;112:337-41.
80. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22:3902-8. (Pubitemid 41079871)
81. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66. (Pubitemid 41095150)
82. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol 2011;22:636-42.
83. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44. (Pubitemid 46630491)
84. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33. (Pubitemid 350299451)
85. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006;103:155-9. (Pubitemid 44374683)
86. Schneider J, Efferth T, Centeno MM, Mattern J, Rodriguez-Escudero FJ, Volm M. High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 1993;29A:554-8. (Pubitemid 23036305)
87. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T et al. Paclitaxel-resistant human ovar ian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25. (Pubitemid 27289821)
88. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157-66.
89. Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15:126-35.
90. Chiva L, Lapuente F, Gonzalez-Cortijo L, Carballo N, Garcia JF, Rojo A et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 2008;111(2 Suppl):S101-4.
91. Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S. Conservative treatment of early endometrial cancer: Preliminary results of a pilot study. Gynecologic Oncology 2011;120:43-46.
92. Perri T, Korach J, Gotlieb WH, Beiner M, Meirow D, Friedman E et al. Prolonged Conservative Treatment of Endometrial Cancer Patients More Than 1 Pregnancy Can Be Achieved. International Journal of Gynecological Cancer 2011;21:72-78.
93. Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option. Gynecological Endocrinology 2009;25:683-91.
94. Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001;24:43-6. (Pubitemid 32178670)
95. Gu C, Zhang Z, Yu Y, Liu Y, Zhao F, Yin L et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Science 2011;102:557-64.
96. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15-20.
97. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008;98:1076-84. (Pubitemid 351399811)
98. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG et al. Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2011;29:2259-65.
99. Delmonte A, Sessa C. Molecule-targeted agents in endometrial cancer. Current Opinion in Oncology 2008;20:554-59.
100. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation- implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-8.